GnRH (Triptorelin) 100mcg

GnRH (triptorelin) is a synthetic peptide analog of the gonadotropin-releasing hormone, or luteinizing hormone-releasing hormone (LHRH). Triptorelin contains 10 amino acids and has a molecular weight of 1310.64 g/mol. The peptide acts as an agonist and binds to gonadotropin-releasing hormone receptors in the pituitary gland to stimulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).¹ Triptorelin is used as a treatment to stimulate an initial release of these hormones, which then triggers a downregulation of receptors.² Over time, this reduces the release of LH and FSH, subsequently inhibiting androgen and estrogen production. Due to its abilities to repress sex hormone production, triptorelin is primarily used in clinical settings as part of prostate cancer treatment, specifically as a first-line androgen deprivation therapy.³ Triptorelin has also been researched for its role in estrogen therapy for treating breast cancer. Studies show that the peptide can be used in combination with tamoxifen (a selective estrogen receptor modulator) to improve prognosis in women with breast cancer.⁴ Due to its estrogen-modulating properties, triptorelin has also been studied for treating endometriosis. Specifically, the peptide reduces nodule volume and pain while improving outcomes after surgery.^5,6 Finally, triptorelin may play a role as a modulator of immune system function. LHRH is known to directly affect the thymus, where T cells are made. Over time, aging contributes to a decrease in thymic mass and a reduction in LHRH receptors on thymic tissues. In a rat research model, dosing with LHRH agonists like triptorelin improved cellular proliferation in the thymus. Researchers hypothesize that this may help recover lost mass and improve immune system function, particularly in older individuals.⁷

Blue Sky Peptide’s GnRH (triptorelin) is available as a white lyophilized powder at a concentration of 100 mcg/vial. GnRH (triptorelin) is intended for in vitro scientific research.

References: 1. National Institute of Diabetes and Digestive and Kidney Diseases. Triptorelin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. March 22, 2018. Accessed from: https://www.ncbi.nlm.nih.gov/books/NBK548756/ 2. Merseburger AS, Hype MC. An update on triptorelin: Current thinking on androgen deprivation therapy for prostate cancer. Adv Ther. 2016;33(7):1072-1093. 3. Ploussard G, Mongiat-Artus P. Triptorelin in the management of prostate cancer. Future Oncol. 2013;9(1):93-102. 4. Frampton JE. Triptorelin: A review of its use as an adjuvant anticancer therapy in early breast cancer. Drugs. 2017;77(18):2037-2048. 5. Xue H, Liu M, Hao W, Li Y. Clinical evaluation of laparoscopic surgery combined with triptorelin acetate in patients with endometriosis and infertility. Pak J Med Sci. 2018;34(5):1064-1069. 6. Maggiore ULR, Scala C, Remorgida V, et al. Triptorelin for the treatment of endometriosis. Expert Opin Pharmacother. 2014;15(8):1153-1179. 7. Marchetti B, Guarcello V, Morale MC, et al. Luteinizing hormone-releasing hormone (LHRH) agonist restoration of age-associated decline of thymus weight, thymic LHRH receptors, and thymocyte proliferative capacity. Endocrinology. 1989;125(2):1037-1045.